Chikungunya Current Affairs - 2020

Indigenously Developed ‘COVAXIN’ gets DCGI approval for Human Clinical Trials

The Drug Controller General of India (DCGI) has given approval for Phase I and Phase II human clinical trials for COVID-19 vaccine ‘COVAXIN’. In association with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), COVAXIN is developed by Hyderabad based vaccine & bio-therapeutics manufacturer-Bharat Biotech.  At NIV Pune, the Read More…

Health Ministry launches Jan Jagrukta Abhiyaan in New Delhi

Union Ministry of Health and Family Welfare (MoHFW) have launched a 3 day special campaign called Jan Jagrukta Abhiyaan in New Delhi. It is a campaign aimed towards sensitizing and mobilising community for prevention and control of vector borne diseases (VBDs) such as Dengue, Chikungunya and Malaria. The 3 day campaign will be held from Read More…

Researchers develop potent molecule to treat chikungunya

Researchers from Indian Institute of Technology (IIT) Roorkee have identified two small potent molecules Pep-I and Pep-II, for their inhibitory activity to treat Chikungunya disease. The antiviral activity of these molecules was so high that their small amount was able to achieve almost 99% reduction in virus. Currently, there are no drugs to treat chikungunya Read More…

IMD to release Malaria and Chikungunya Alerts

The India Meteorological Department (IMD) has announced that it is working on a forecasting system that will give a 15-day warnings on the likelihood of a malaria or chikungunya outbreak across different regions of the country. Salient Highlights The services are aimed at providing custom, weather-related information to cope with challenges of a global warming and its Read More…

Tags:

Genetically Modified mosquito trials launched to control dengue, chikungunya and zika

Outdoor caged trials of genetically modified mosquitoes waere launched in Dawalwadi, Badnapur in Jalna district of Maharashtra to demonstrate the efficiency this technique to suppress wild female mosquito populations that transmit dengue, chikungunya and Zika. The trials are conducted by Oxitec and uses the Release of Insects carrying Dominant Lethal genes (RIDL) technology. Key Facts Read More…